Researchers found that adding nintedanib – a targeted cancer growth inhibitor currently used to treat non-small cell lung cancer – to chemotherapy, could significantly improve overall survival rate for bladder cancer patients.
- Phase two randomised placebo controlled trial (NEOBLADE) showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years
- Nintedanib belongs to a group of targeted therapy drugs known as cancer growth inhibitors which are already used to treat non-small cell lung cancer
- The inhibitor blocks different proteins from sending signals to the cancer cells to grow causing the cancer cells to die
Scientists from the University of Sheffield have discovered a drug already used to treat lung cancer could help to improve survival rates for bladder cancer patients.
Researchers found that adding nintedanib – a targeted cancer growth inhibitor currently used to treat non-small…
